Overview

Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

Hypothesis Combination of Boceprevir with Ribavirin in treatment-naïve patients with genotype 4 chronic hepatitis C infection will increase the proportion of patients achieving sustained viral response compared to standard treatment alone.

Phase:

Phase 3

Details

Lead Sponsor:

Theodor Bilharz Research Institute

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin